{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:59:19Z","timestamp":1791233959562,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573732"],"award-info":[{"award-number":["82573732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["KA0120231004"],"award-info":[{"award-number":["KA0120231004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2024ZD0529400"],"award-info":[{"award-number":["2024ZD0529400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241235"],"award-info":[{"award-number":["82241235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503897"],"award-info":[{"award-number":["82503897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eclinm.2026.103994","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:53:54Z","timestamp":1779936834000},"page":"103994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE\/CTONG2104): phase II trial and correlative genomic analysis in China"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-5647","authenticated-orcid":false,"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Yuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Xu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Shan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri-Qiang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-176X","authenticated-orcid":false,"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1818-616X","authenticated-orcid":false,"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103994_bib1","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/JTO.0b013e31815e5d9a","article-title":"Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer","volume":"3","author":"Detterbeck","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103994_bib6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/JTO.0b013e3181cd3345","article-title":"Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials","volume":"5","author":"Song","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicentre, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.eclinm.2026.103994_bib9","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.24.00071","article-title":"Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicentre study","volume":"42","author":"Blakely","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib10","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103994_bib12","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib13","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41591-025-03658-y","article-title":"Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial","volume":"31","author":"Zhou","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41467-017-02584-z","article-title":"Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing","volume":"9","author":"Nahar","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.103994_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41588-019-0569-6","article-title":"Genomic landscape of lung adenocarcinoma in East Asians","volume":"52","author":"Chen","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.eclinm.2026.103994_bib22","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1038\/s41467-021-26806-7","article-title":"Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.103994_bib23","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.22.00428","article-title":"Updated overall survival and exploratory analysis from randomized, phase II EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage IIIA epidermal growth factor receptor+ non-small-cell lung cancer","volume":"40","author":"Yue","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib24","article-title":"Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: phase 2 trial interim results (NEOTIDE\/CTONG2104)","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib25","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"Fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.eclinm.2026.103994_bib26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2026.103994_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.eclinm.2026.103994_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"10.1016\/j.eclinm.2026.103994_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41698-023-00465-x","article-title":"Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma","volume":"7","author":"Feng","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib30","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"10.1016\/j.eclinm.2026.103994_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13059-016-0893-4","article-title":"DeconstructSigs: delineating mutational processes in single tumours distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"Rosenthal","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.eclinm.2026.103994_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-018-0539-0","article-title":"MutationalPatterns: comprehensive genome-wide analysis of mutational processes","volume":"10","author":"Blokzijl","year":"2018","journal-title":"Genome Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib33","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","article-title":"OptiType: precision HLA typing from next-generation sequencing data","volume":"30","author":"Szolek","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.eclinm.2026.103994_bib34","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumour-informed circulating tumour DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eclinm.2026.103994_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41392-022-01286-3","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial","volume":"8","author":"Zhong","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eclinm.2026.103994_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103994_bib37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/PO.20.00261","article-title":"Individualized molecular profiling for allocation to clinical trials Singapore study-an Asian tertiary cancer centre experience","volume":"5","author":"Seet","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41571-022-00718-x","article-title":"At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC","volume":"20","author":"Otano","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","article-title":"Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients","volume":"8","author":"Hong","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib41","doi-asserted-by":"crossref","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumour mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2026.103994_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2018.09.010","article-title":"Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer","volume":"125","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.eclinm.2026.103994_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.eclinm.2026.103994_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2026.103994_bib45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","article-title":"Role of the dynamic tumour microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations","volume":"18","author":"Lin","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.eclinm.2026.103994_bib46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib47","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumour heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.103994_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2392898","article-title":"Tertiary lymphoid structure-related immune infiltrates in NSCLC tumour lesions correlate with low tumour-reactivity of TIL products","volume":"13","author":"Castenmiller","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.eclinm.2026.103994_bib49","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41392-023-01700-4","article-title":"Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicentre open-label phase II study","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eclinm.2026.103994_bib50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib51","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib52","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicentre phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eclinm.2026.103994_bib53","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.2147\/CMAR.S255967","article-title":"Concomitant mutations in EGFR 19 Del\/L858R mutation and their association with response to EGFR-TKIs in NSCLC patients","volume":"12","author":"Liang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.eclinm.2026.103994_bib54","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ebiom.2019.03.023","article-title":"Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive non-small cell lung cancer","volume":"42","author":"Chen","year":"2019","journal-title":"eBioMedicine"},{"key":"10.1016\/j.eclinm.2026.103994_bib55","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumour DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eclinm.2026.103994_bib56","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicentre cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.103994_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.055","article-title":"LBA59 associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial","volume":"34","author":"Reck","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib58","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2024.42.16_suppl.8005","article-title":"Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB\u2013IIIA non-small cell lung cancer (NSCLC)","volume":"42","author":"John","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib59","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103994_bib60","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib61","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jtho.2022.01.012","article-title":"Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicentre trial","volume":"17","author":"Ahn","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.eclinm.2026.103994_bib62","article-title":"Immune cell dynamics in EGFR-mutated NSCLC treated with afatinib and pembrolizumab: results from a phase IB study","volume":"5","author":"Riess","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.eclinm.2026.103994_bib63","article-title":"Adjuvant osimertinib in patients with stage IB to IIIA EGFR mutation-positive NSCLC after complete tumour resection: ADAURA China subgroup analysis","volume":"5","author":"Wang","year":"2024","journal-title":"JTO Clin Res Rep"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:31:08Z","timestamp":1791232268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026002427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":63,"alternative-id":["S2589537026002427"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103994","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE\/CTONG2104): phase II trial and correlative genomic analysis in China","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103994"}}